Biologie moléculaire des syndromes myélodysplasiques

Myelodysplatic syndromes (MDS) represent a heterogeneous group of clonal myeloid hemopathies associated with a high risk of progression to an acute myeloid leukemia. Molecular abnormalities in MDS are not well characterized and may represent markers of progression to acute myeloid leukemia. Positive clinical results obtained with therapeutic agents inhibiting DNA methylation preservation during cell division have reinforced the interest of studying epigenetic abnormalities in MDS. New strategies based on hight throughput sequencing should allow rapid advances in moleculare characterization of MDS and could improve understanding of their physiopathology. These new technologies should be implemented in routine practice for prognosis prediction and therapeutic purposes.